Anzeige
Mehr »
Login
Samstag, 09.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
4.000 Meilen, um herauszufinden, warum der „Warren Buffett des Bergbaus" in diese Kupferaktie investierte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
592 Leser
Artikel bewerten:
(2)

Celonis Announces $1 Billion Round to Meet Industry-Wide Demand for Execution Management

Finanznachrichten News

Appoints Google Executive and Former Wall Street Analyst Carlos Kirjner as Celonis Chief Financial Officer

NEW YORK and MUNICH, June 2, 2021 /PRNewswire/ -- Celonis, the global leader in execution management, today announced a $1 billion Series D round, increasing its post-money valuation to more than $11 billion. In addition, Carlos Kirjner, a technology industry veteran and former top-ranked Wall Street analyst, joined as Chief Financial Officer from Google, where he led finance for its flagship advertising business and key product areas.

This round comes just six months after Celonis launched its groundbreaking new product, the Execution Management System (EMS), which provides companies a modern way to run their business processes entirely on data and intelligence. The new Celonis EMS addresses the fundamental limitations of running business processes across a complex set of aging and fragmented transaction systems, devices and edge applications, and triggered the creation of the execution management industry.

New Celonis investors Durable Capital Partners LP and T. Rowe Price Associates co-led the round, with participation from Franklin Templeton, Splunk Ventures and a group of principal investors. Also joining the round were existing investors including Arena Holdings.

"Celonis uniquely sits at the center of one of the biggest technology trends of our time -- modernizing businesses with data-driven and intelligent execution," said Henry Ellenbogen, the Managing Partner and Chief Investment Officer of Durable Capital Partners. "Celonis is a rare gem that has a massive market potential to create a new and modern way to run your business."

"As companies grow, inefficiency creeps in and business execution becomes a struggle. Employees feel it, customers feel it, and it leads to significant financial losses and environmental impact," said Alex Rinke, co-CEO and co-founder of Celonis. "We are thrilled and honored that the rise of execution management is defining a new software stack that helps customers reimagine how they execute. It is the biggest shift in software since cloud computing."

"Business execution is what sets the leaders apart from the laggards," said Carsten Thoma, co-founder of Hybris and Celonis board member. "No transformation can happen without fixing the processes that drive day-to-day execution. That's why Celonis is in such a unique position to lead the execution management category."

Celonis pioneered the process mining category 10 years ago when it first developed the ability to automatically X-ray process problems. Today Celonis is leveraging this foundation to pioneer the execution management industry and change business processes. Celonis is growing by triple digits year-over-year. Thousands of organizations have adopted Celonis including Fortune 500 companies such as Danaher, Dell, Kimberly-Clark, L'Oréal, and Pfizer. Celonis has more than 1,300 global employees and is headquartered in New York and Munich.

Appoints Carlos Kirjner as Chief Financial Officer

Carlos Kirjner joins Celonis as its new Chief Financial Officer to guide the company through its next stage of hyper growth. Kirjner most recently served as vice president of finance at Google, where he led finance for business and product areas generating about $150 billion annually in revenue and was responsible for tens of thousands of employees. He covered Google's advertising business, including engineering and sales; Google Search; and Google Maps.

Before Google, Carlos worked at Sanford C. Bernstein & Co. as the No. 1-ranked equity research analyst covering the Internet sector, and he was one of the first analysts to call out the importance of the cloud. He started his career at McKinsey & Co. in the late 1990s, where he was a partner in the tech and telecom practices. Carlos holds a PhD in Electrical Engineering and Computer Sciences from the University of California at Berkeley.

As part of the executive management team, Kirjner will be responsible for the global finance organization and strategy.

"Carlos is a visionary business leader with a proven track record of spotting some of the biggest industry trends long before others and of operating in a fast-moving environment at scale," said Bastian Nominacher, co-CEO and co-founder of Celonis. "He has the foresight and experience to drive our ambitious goals of being a category-defining company that is built for long-term growth and impact."

Creating Customer Value and Momentum

The company's growth and innovation have triggered clear momentum for the execution management category.

Thousands of customers are shifting their spending away from the legacy stack dominated by aging and rigid transaction systems to running their businesses with modern execution management systems. In the last six months, more than 40,000 business execution and process experts attended the Celonis Execution Management World Tour and Celosphere 2021, the industry's first execution management conference.

At Celosphere, Celonis announced that customers were eliminating billions in corporate inefficiencies by modernizing process execution. Celonis also launched the breakthrough $10 Million Dollar Execution Capacity Challenge, where Celonis will either find $10 million in trapped capacity or donate $100,000 to a joint charity.

Driving Industry Ecosystem Standardization

The entire business consulting and integration industry is quickly adopting Celonis as the standard of excellence for modernizing their customers' business execution. In March 2021, IBM and Red Hat announced a strategic partnership with Celonis to transform business execution for their global customers.

In April 2021, Celonis announced its Execution Management Without Limits program that will enable more than one million business consultants to conduct customer engagement with Celonis process mining and execution management products. And in just six months, since launching the Celonis Studio, the execution management ecosystem has developed more than 80 execution applications and hundreds more are in development.

Attracting CEO and Executive Alignment

The most senior CEOs and successful business operators are aligning to help set new standards and best practices in applying data and intelligence to execution with Celonis. Celonis recently announced the formation of the Celonis Business Execution CEO Council with a legendary group of Fortune 500 business operators to support the Celonis business execution agenda.

Celonis Funding History

The Series D follows previous investment rounds of $290 million from a Series C in November 2019, $50 million from a Series B in June 2018, and $27.5 million from a Series A in June 2016.

About Celonis

Celonis believes that every company can unlock its full execution capacity. Powered by its market-leading process mining core, the Celonis Execution Management System provides a set of applications, and developer studio and platform capabilities for business executives and users to eliminate billions in corporate inefficiencies. Celonis has thousands of customers, including ABB, AstraZeneca, Bosch, Coca-Cola, Citibank, Danaher Corporation, Dell, GSK, John Deere, L'Oréal, Siemens, Uber, Vodafone and Whirlpool. Celonis is headquartered in Munich, Germany and New York City, USA and has 15 offices worldwide.

Contact:
Isabell Horvath
Director, Global Communications
press@celonis.com

Logo - https://mma.prnewswire.com/media/1312282/Celonis_Logo.jpg

© 2021 PR Newswire
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.